Effective screening for the development of early onset preeclampsia (PE) can be provided in
the first‐trimester of pregnancy. Screening by a combination of maternal risk factors, uterine …

Preeclampsia (PE), which affects about 2% of pregnancies, is a major cause of maternal and
perinatal morbidity and mortality. PE can be subdivided into early onset PE with delivery< 34 …

Although the precise pathophysiology of pre-eclampsia remains unknown, this condition
continues to be a major cause of maternal and fetal mortality. Early prediction of pre …

Objective To define the contribution of maternal variables which influence the measured
level of maternal serum pregnancy‐associated plasma protein‐A (PAPP‐A) in screening for …

Aim: To assess a maternal serum level of high sensitive C‐reactive protein (hs‐CRP) as a
useful clinical parameter in prediction of pre‐eclampsia severity and, to evaluate the …

Materials and methods: Serum levels of uhsCRP, IL-6, PLGF, VEGF and s-Flt-1 were
longitudinally determined in 16 women with normal, singleton healthy pregnancies at 7–13 …

In order to identify new protein markers modified in placental diseases, high-throughput
analysis of proteins in the plasma of pregnant women was carried out for normal and …

Pregnancy-associated plasma protein A (PAPP-A) is a key regulator of insulin-like growth
factor bioavailability essential for normal fetal development. In maternal blood, this protein …

Objective To examine the distribution of maternal serum pregnancy‐associated plasma
protein‐A (PAPP‐A) and free β‐human chorionic gonadotropin (β‐hCG) at 12, 22 and 32 …

Aim The purpose of the present study was to evaluate the diagnostic value of maternal
serum high‐sensitivity C‐reactive protein (hs‐CRP) measurement during the first trimester of …